National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (Cth)
Case
No judgment structure available for this case.
PB 111 of 2023
National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023
I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 30 October 2023
Eden Simon
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged CareContents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Minimum Stockholding) Determination 2023 2
1 Name
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023.
(2) This instrument may also be cited as PB 111 of 2023.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this instrument 1 November 2023. 1 November 2023
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Minimum Stockholding) Determination 2023
1 Schedule 1 (table)
Repeal the table, substitute:
| Applicable quantity of a brand of a pharmaceutical item | ||||
| Column 1 Drug | Column 2 Form | Column 3 Manner of administration | Column 4 Brand | Column 5 Applicable quantity |
| Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Fosamax Plus | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Allosig | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 100 mg | Oral | Zyloprim | 3 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Allopurinol APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Allopurinol | Tablet 300 mg | Oral | Zyloprim | 4 months stock by reference to usual demand |
| Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |
| Amisulpride | Tablet 100 mg | Oral | Amisulpride 100 Winthrop | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Amisulpride | Tablet 400 mg | Oral | Amisulpride 400 Winthrop | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | APX‑Amitriptyline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | ENTRIP | 4 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amoxicillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral | Amoxil | 4 months stock by reference to usual PBS demand |
| Amphotericin B | Lozenge 10 mg | Oral | Fungilin | 4 months stock by reference to usual PBS demand |
| Anastrozole | Tablet 1 mg | Oral | Anastrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 10 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 15 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Aripiprazole | Tablet 20 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral | Atenolol‑AFT | 4 months stock by reference to usual PBS demand |
| Atenolol | Tablet 50 mg | Oral | APX‑Atenolol | 4 months stock by reference to usual demand |
| Atenolol | Tablet 50 mg | Oral | Tensig | 4 months stock by reference to usual demand |
| Atomoxetine | Capsule 10 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 100 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 18 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 25 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 40 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 60 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |
| Atorvastatin | Tablet 20 mg (as calcium) | Oral | Atorvastatin GH | Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand |
| Azathioprine | Tablet 50 mg | Oral | Azathioprine GH | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax | 4 months stock by reference to usual PBS demand |
| Baclofen | Tablet 10 mg | Oral | APO‑Baclofen | 3 months stock by reference to usual demand |
| Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | APO‑Candesartan | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | APO‑Candesartan | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | CANDESAN | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
| Carboplatin | Solution for I.V. injection 450 mg in 45 mL | Injection | DBL Carboplatin | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | 4 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | 4 months stock by reference to usual PBS demand |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |
| Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO‑Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime‑AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the Eye | Chlorsig | 4 months stock by reference to usual PBS demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 10 mg | Oral | Largactil | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Chlorpromazine | Tablet containing chlorpromazine hydrochloride 25 mg | Oral | Largactil | 4 months stock by reference to usual PBS demand |
| Chlortalidone | Tablet 25 mg | Oral | Hygroton 25 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 10 mg | Oral | Neoral 10 | 4 months stock by reference to usual PBS demand |
| Ciclosporin | Capsule 100 mg | Oral | APO‑Ciclosporin | 2.5 months stock by reference to usual demand |
| Ciclosporin | Capsule 25 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Capsule 50 mg | Oral | APO‑Ciclosporin | 3 months stock by reference to usual demand |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |
| Clopidogrel | Tablet 75 mg (as besilate) | Oral | Clopidogrel GH | Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | Oral | CLOPIDOGREL/ASPIRIN AN 75/100 | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharma Pty Ltd | 4 months stock by reference to usual PBS demand |
| Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
| Desferrioxamine | Powder for injection containing desferrioxamine mesilate 2 g | Injection | DBL Desferrioxamine Mesilate | between 1 July 2023 and 31 July 2023—4 months stock by reference to usual demand |
| Dexamethasone with framycetin and gramicidin | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the Ear | Sofradex | between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Fenac | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxorubicin ‑ pegylated liposomal | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | Injection | Liposomal Doxorubicin SUN | 3 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX‑Doxycycline | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | APX‑Doxycycline | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 10 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | APO‑Enalapril | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 20 mg | Oral | Malean | 3 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | APO‑Enalapril | 4 months stock by reference to usual demand |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTAC | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | 4 months stock by reference to usual PBS demand |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |
| Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | APO‑Ezetimibe/Simvastatin 10/10 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | Zeklen 10/10 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | APO‑Ezetimibe/Simvastatin 10/20 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | Zeklen 10/20 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | APO‑Ezetimibe/Simvastatin 10/40 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | Zeklen 10/40 mg | between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | APO‑Ezetimibe/Simvastatin 10/80 | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Vytorin | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
| Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Zeklen 10/80 mg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg | 2.5 months stock by reference to usual demand |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
| Filgrastim | Injection 300 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 300 micrograms in 1 mL | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 480 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 480 micrograms in 1.6 mL | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Flucloxacillin | Powder for injection 1 g (as sodium monohydrate) | Injection | Flucil | between 1 July 2023 and 30 November 2023—4 months stock by reference to usual demand |
| Flucloxacillin | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Flucloxacillin | Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | 2 months stock by reference to usual PBS demand |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | 4 months stock by reference to usual PBS demand |
| Fluorouracil | Injection 2500 mg in 50 mL | Injection | DBL Fluorouracil Injection BP | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Blooms the Chemist Fluoxetine | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Folic acid | Tablet 5 mg | Oral | Megafol 5 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Foltabs 500 | 4 months stock by reference to usual PBS demand |
| Folic acid | Tablet 500 micrograms | Oral | Megafol 0.5 | 4 months stock by reference to usual PBS demand |
| Fosinopril | Tablet containing fosinopril sodium 10 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Fosinopril | Tablet containing fosinopril sodium 20 mg | Oral | APO‑Fosinopril | 3 months stock by reference to usual demand |
| Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the Eye/Ear | Soframycin | 4 months stock by reference to usual PBS demand |
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
| Gabapentin | Capsule 100 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Gabapentin | Capsule 300 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |
| Gemfibrozil | Tablet 600 mg | Oral | Lipigem | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
| Glimepiride | Tablet 3 mg | Oral | Amaryl | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | Amaryl | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |
| Glucose indicator‑urine | Test strips, 50 (Diastix) | For External Use | Diastix | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 1.5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 5 mg | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Haloperidol | Tablet 500 micrograms | Oral | Serenace | 4 months stock by reference to usual PBS demand |
| Heparin | Injection 5,000 units (as sodium) in 0.2 ml | Injection | DBL Heparin Sodium | 6 months stock by reference to usual PBS demand |
| Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | 4 months stock by reference to usual PBS demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | Genteal | 4 months stock by reference to usual demand |
| Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the Eye | In a Wink Moisturising | 4 months stock by reference to usual demand |
| Ibuprofen | Tablet 400 mg | Oral | APO‑Ibuprofen 400 | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib‑APOTEX | 3 months stock by reference to usual demand |
| Indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Insig | 3 months stock by reference to usual demand |
| Insect allergen extract‑honey bee venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Honey Bee Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract‑paper wasp venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Paper Wasp Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Insulin glargine | Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Insulin glargine | Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Irbesartan with hydrochlorothiazide | Tablet 300 mg‑25 mg | Oral | AVSARTAN HCT 300/25 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Labetalol | Tablet containing labetalol hydrochloride 200 mg | Oral | Trandate | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | 3 months stock by reference to usual demand |
| Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost | 2 months stock by reference to usual demand |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Monofeme 28 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets | Oral | Lenest 30 ED | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
| Lithium | Tablet containing lithium carbonate 250 mg | Oral | Lithicarb | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Losartan | Tablet containing losartan potassium 25 mg | Oral | Cozavan | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral | Movicol Liquid | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | APX‑Meloxicam | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
| Methotrexate | Injection 50 mg in 2 mL vial | Injection | Methotrexate Accord | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Metrol 50 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Modafinil | Tablet 100 mg | Oral | Modafin | 3 months stock by reference to usual demand |
| Morphine | Tablet containing morphine sulfate pentahydrate 30 mg | Oral | Anamorph | 3 months stock by reference to usual demand |
| Mycophenolic Acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | CellCept | between 1 July 2023 and 30 September 2023—4 months stock by reference to usual PBS demand |
| Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral | Viramune | 4 months stock by reference to usual PBS demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | APO‑Nicorandil | 2 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |
| Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO‑Olanzapine ODT | 3 months stock by reference to usual demand |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Olanzapine ODT generichealth 5 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMERTAN | 3 months stock by reference to usual demand |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | APX‑Olmesartan/HCTZ | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 20/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMERTAN COMBI 40/12.5 | 3 months stock by reference to usual demand |
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMERTAN COMBI 40/25 | 3 months stock by reference to usual demand |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | DBL Oxaliplatin Concentrate | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | APO‑Oxazepam | 5.5 months stock by reference to usual demand |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
| Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | 4 months stock by reference to usual PBS demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Paracetamol | Tablet 665 mg (modified release) | Oral | CHEMISTS' OWN OSTEO RELIEF PARACETAMOL | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
| Pemetrexed | Powder for I.V. infusion 100 mg (as disodium) | Injection | Pemetrexed‑AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Pemetrexed | Powder for I.V. infusion 500 mg (as disodium) | Injection | Pemetrexed‑AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 4 months stock by reference to usual PBS demand |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Perindopril generichealth | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Perindopril generichealth | |
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | APO‑Perindopril Arginine/Amlodipine 5/10 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |
| Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg‑3 mg per mL, 15 mL | Application to the Eye | Systane | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | Liquifilm Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | PVA Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
| Probenecid | Tablet 500 mg | Oral | Pro‑Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Quinapril | Tablet 10 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Quinapril | Tablet 20 mg (as hydrochloride) | Oral | APO‑Quinapril | 3 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO‑Rabeprazole | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
| Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO‑Rabeprazole | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | RALOVISTA | 3 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | APX‑Ramipril | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Prilace | 2.5 months stock by reference to usual demand |
| Ramipril | Tablet 1.25 mg | Oral | Tryzan Tabs 1.25 | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—3 months stock by reference to usual demand |
| Ramipril | Tablet 2.5 mg | Oral | APO‑Ramipril | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Tablet 5 mg | Oral | Prilace | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |
| Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | Zantac Syrup | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual PBS demand |
| Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO‑Risedronate | 3 months stock by reference to usual demand |
| Risperidone | Tablet 1 mg | Oral | APO‑Risperidone | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
| Risperidone | Tablet 4 mg | Oral | Rispa | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | APX‑Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APX‑Rosuvastatin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crosuva 5 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
| Roxithromycin | Tablet 150 mg | Oral | APX‑Roxithromycin | 4 months stock by reference to usual demand |
| Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Roxithromycin | Tablet for oral suspension 50 mg | Oral | Rulide D | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO‑Sumatriptan | 4 months stock by reference to usual demand |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrograf | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
| Telmisartan with hydrochlorothiazide | Tablet 80 mg‑25 mg | Oral | Telmisartan HCT GH 80/25 | between 1 July 2023 and 30 September 2023—0 months stock by reference to usual demand |
| Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |
| Temozolomide | Capsule 180 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Temozolomide | Capsule 250 mg | Oral | Temodal | between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |
| Tobramycin | Injection 80 mg in 2 mL | Injection | DBL Tobramycin | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Topiramate | Tablet 100 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 200 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 25 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Topiramate | Tablet 50 mg | Oral | APO‑Topiramate | 3 months stock by reference to usual demand |
| Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral | Tramal | 4 months stock by reference to usual PBS demand |
| Trandolapril | Capsule 1 mg | Oral | Dolapril 1 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 2 mg | Oral | Dolapril 2 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 4 mg | Oral | Dolapril 4 | 3 months stock by reference to usual demand |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |
| Triglycerides ‑ medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | after 30 November 2023—6 months stock by reference to usual PBS demand |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | 4 months stock by reference to usual PBS demand |
| Valproic acid | Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Syrup | 4 months stock by reference to usual PBS demand |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |
| Voriconazole | Tablet 50 mg | Oral | Vfend | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
2 Schedule 1
After:
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | 4 months stock by reference to usual PBS demand |
insert:
| Cefaclor | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Oral | APO-Cefaclor | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cefaclor | Tablet (sustained release) 375 mg (as monohydrate) | Oral | APO-Cefaclor CD | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
3 Schedule 1
After:
| Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO‑Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
insert:
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime-AFT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
4 Schedule 1
After:
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharma Pty Ltd | 4 months stock by reference to usual PBS demand |
insert:
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | APO-Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | GenRx Cyproterone Acetate | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | APO-Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | GenRx Cyproterone Acetate | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
5 Schedule 1
After:
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
insert:
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Diclofenac Sandoz | between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Diclofenac Sandoz | between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand |
6 Schedule 1
After:
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
insert:
| Doxycycline | Tablet 100 mg (as monohydrate) | Oral | APO-Doxycycline | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
7 Schedule 1
After:
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |
insert:
| Doxycycline | Tablet 50 mg (as monohydrate) | Oral | APO-Doxycycline | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
8 Schedule 1
After:
| Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand |
insert:
| Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Apotex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Apotex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
9 Schedule 1
After:
| Filgrastim | Injection 480 micrograms in 1.6 mL | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
insert:
| Flucloxacillin | Capsule 250 mg (as sodium monohydrate) | Oral | APO-Flucloxacillin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
10 Schedule 1
After:
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
insert:
| Furosemide | Tablet 20 mg | Oral | Urex-M | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Furosemide | Tablet 40 mg | Oral | Urex | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Gabapentin | Capsule 100 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
11 Schedule 1
After:
| Gabapentin | Capsule 100 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand |
insert:
| Gabapentin | Capsule 300 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
12 Schedule 1
After:
| Gabapentin | Capsule 300 mg | Oral | GAPENTIN | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
insert:
| Gabapentin | Capsule 400 mg | Oral | Gabapentin APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
13 Schedule 1
After:
| Insulin glargine | Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
insert:
| Ipratropium | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | APO-Ipratropium | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ipratropium | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | APO-Ipratropium | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
14 Schedule 1
After:
| Labetalol | Tablet containing labetalol hydrochloride 200 mg | Oral | Trandate | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
insert:
| Lamotrigine | Tablet 100 mg | Oral | APO-Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 200 mg | Oral | APO-Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 25 mg | Oral | APO-Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 50 mg | Oral | APO-Lamotrigine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
15 Schedule 1
After:
| Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral | Movicol Liquid | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
insert:
| Macrogol 3350 | Powder for oral solution 510 g | Oral | OsmoLax | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
16 Schedule 1
After:
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
insert:
| Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metformin XR 500 APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 1 g | Oral | APO-Metformin 1000 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | APO-Metformin 500 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | APO-Metformin 850 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
17 Schedule 1
After:
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Metrol 50 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
insert:
| Mirtazapine | Tablet 15 mg | Oral | APO-Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 30 mg | Oral | APO-Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Mirtazapine | Tablet 45 mg | Oral | APO-Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Moclobemide | Tablet 150 mg | Oral | APO-Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Moclobemide | Tablet 300 mg | Oral | APO-Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
18 Schedule 1
After:
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
insert:
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | APO-Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
19 Schedule 1
After:
| Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
insert:
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | APO-Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
20 Schedule 1
After:
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
insert:
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
21 Schedule 1
After:
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |
insert:
| Oxybutynin | Tablet containing oxybutynin hydrochloride 5 mg | Oral | Ditropan | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
| Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL | Oral | OxyNorm Liquid 1mg/mL | 4 months stock by reference to usual PBS demand |
22 Schedule 1
After:
| Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | PVA Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
insert:
| Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | APO-Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 20 mg | Oral | APO-Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 40 mg | Oral | APO-Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pravastatin | Tablet containing pravastatin sodium 80 mg | Oral | APO-Pravastatin | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pregabalin | Capsule 150 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pregabalin | Capsule 25 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pregabalin | Capsule 300 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Pregabalin | Capsule 75 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
23 Schedule 1
After:
| Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO‑Rabeprazole | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
insert:
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | APO-Raloxifene | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
24 Schedule 1
After:
| Risperidone | Tablet 1 mg | Oral | APO‑Risperidone | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
insert:
| Risperidone | Tablet 1 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
| Risperidone | Tablet 2 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
25 Schedule 1
After:
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
insert:
| Risperidone | Tablet 3 mg | Oral | Risperidone generichealth | between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand |
26 Schedule 1
After:
| Sodium acid phosphate | Tablet, compound effervescent, equivalent to 500 mg phosphorus | Oral | PHOSPHATE PHEBRA | after 30 November 2023—6 months stock by reference to usual PBS demand |
insert:
| Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | Rectal | Micolette | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | APO-Sotalol | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
27 Schedule 1
After:
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand; (b) after 31 December 2023—1.5 months stock by reference to usual demand |
insert:
| Sotalol | Tablet containing sotalol hydrochloride 80 mg | Oral | APO-Sotalol | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
28 Schedule 1
After:
| Voriconazole | Tablet 50 mg | Oral | Vfend | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
insert:
| Ziprasidone | Capsule 20 mg (as hydrochloride) | Oral | APO-Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 40 mg (as hydrochloride) | Oral | APO-Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 60 mg (as hydrochloride) | Oral | APO-Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Ziprasidone | Capsule 80 mg (as hydrochloride) | Oral | APO-Ziprasidone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
Actions
Download as PDF
Download as Word Document
Cases Citing This Decision
0
Cases Cited
0
Statutory Material Cited
0